Torcetrapib Clinical Trials

Size	Price	Qty
10mg	USD 170

Clinical Trials

Pfizer sponsored numerous late-stage Phase 3 clinical trials evaluating torcetrapib, both alone and in combination with statin therapy, for metabolic and cardiovascular conditions including hyperlipidemia, dyslipidemia, coronary disease, and diabetes mellitus. Although several clinical trials reached completion, key studies were terminated early due to adverse safety outcomes, specifically increased cardiovascular events and mortality.

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT00134264	TERMINATED	Coronary Disease; Diabetes Mellitus	Pfizer	2004-07	PHASE3
NCT00267280	TERMINATED	Hyperlipidemia; Dyslipidemia; Hypercholesterolemia	Pfizer	2006-01	PHASE3
NCT00145431	TERMINATED	Hyperlipoproteinemia Type III	Pfizer	2005-03	PHASE3
NCT00134238	TERMINATED	Mixed Hyperlipidemia	Pfizer	2003-11	PHASE3
NCT00138762	COMPLETED	Hyperlipidemia	Pfizer	2004-07	PHASE3
NCT00139061	Completed	Hyperlipidemia	Pfizer	2005-03	Phase 3
NCT00267254	COMPLETED	Hyperlipidemia; Dyslipidemia; Hypercholesterolemia	Pfizer	2006-01	PHASE3
NCT00134173	COMPLETED	Coronary Disease; Coronary Arteriosclerosis; Hyperlipidemia	Pfizer	2003-10	PHASE3
NCT00139061	COMPLETED	Hyperlipidemia	Pfizer	2005-03	PHASE3
NCT00134498	COMPLETED	Hypertriglyceridemia; Hyperlipoproteinemia Type IV	Pfizer	2005-02	PHASE3
NCT00267267	TERMINATED	Hyperlipidemia; Dyslipidemia	Pfizer	2006-01	PHASE3
NCT00137462	COMPLETED	Hyperlipidemia	Pfizer	2004-11	PHASE3
NCT00134511	COMPLETED	Hypercholesterolemia, Familial	Pfizer	2005-03	PHASE3
NCT00134485	COMPLETED	Hypercholesterolemia, Familial; Hyperlipidemia	Pfizer	2005-03	PHASE3
NCT00136981	COMPLETED	Hypercholesterolemia, Familial; Hyperlipidemia	Pfizer	2003-12	PHASE3

(data from https://clinicaltrials.gov, updated on 2012-02-03)

Check the Torcetrapib product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

Torcetrapib is a potent inhibitor of cholesterylester transfer protein (CETP) that binds directly to the enzyme and blocks the transfer of cholesteryl esters from high-density lipoproteins (HDL) to low-density and very-low-density lipoproteins (LDL/VLDL). This inhibition elevates plasma HDL-cholesterol levels and reduces pro-atherogenic non-HDL cholesterol, which directly targets the lipid imbalances associated with hyperlipidemia, dyslipidemia, and coronary artery disease evaluated in late-stage clinical trials.

Appendix RUO and cGMP Quality Standards

Quality Dimension	RUO (Research Use Only)	cGMP (Current Good Manufacturing Practice)
Clinical Applicability	Prohibited in human clinical trials or medical diagnostics.	Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status	Non-regulated grade; exempt from drug manufacturing laws.	Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment	Unclassified analytical or research laboratories.	Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control	Basic purity and activity testing.	Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation	Basic equipment calibration; no process validation required.	Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance	Vendor self-declared without required formal QMS.	Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact	High risk of IND rejection if used as a critical raw material.	Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).